Q2 2020 Amneal Pharmaceuticals Inc Earnings Call
All participants will be in listen only mode.
And you need assistance. Please ignore conference specialist by pressing the star key followed by zero.
After todays presentation, there will be an opportunity to ask question.
Please note that this event is being recorded.
I'm not like to turn the conference over to MLS Chief Financial Officer, Mr. Tussles Kinda Charles Please go ahead.
Good morning, thank him for joining us. It then nucor Emil second quarter 2020, Onek School earlier. This morning, we issued a press release importing of quarterly results.
Craig list as well as this like the will decrease I don't recall that available on our website.
Good W.W.M. they'll dot com.
Conducting a live webcast on this call.
Which will also be available on our website after its conclusion.
Please note today's call is copyrighted material opened meal.
And I feel rebroadcast without the company's expressed written consent.
I'd like to remind you that statements made during this call, stating managements outlook corporate pictures.
Periods.
<unk> looking statements.
Statements are based solely on information that is now available to us.
Encourage you to review the section entitled Cautionary statements are forward looking statements no question, releasing presentation, which applies to the school.
Appears or four months, maybe they forget the numbers Dr. <unk> many of which are listed on our most recent annual report on form 10-K.
No we buy.
Based on a quarterly reports on form 10-Q, and current reports on form 8-K.
Did you can also find another website or necessary is website.
She doesn't go.
We also discuss certain non-GAAP measures you will find important information and not unusual mismatch. There was another were conciliation do you just got no telling stories.
Included in the appendix of today's presentation, you will find U.S. GAAP financial statements to correspond to some of our non U.S. GAAP measures we were at British throughout the presentation.
Well the call this morning, Horseshoe rock to propel our casinos.
And the boiler in Jochen the scope chip commercial source of our generics and specialty segments respectively.
As well as Steve Mcdonnell our general counsel in corporate Secretary.
I would now like to turn the call it works you're right.
Thank you got sodas and good morning, everyone hope everyone is safe and healthy. Thank you for joining yesterday, we were having in second quarter results I'm pleased to report solid top and bottom line results wouldn't actually almost 465 million.
15% worse since Q2, 2019, I'd, just say that Green Dot 101 building up 9% existing yeah, so predicting signs up 44%.
Overall or business performed in line with our expectation I could've collects and what organizational focus and resiliency during the meeting they moved <unk> patients against hybrids and electric to covert 19 pandemic.
This solid performance reflects the started strong foundation on the complete end to grow division that Jim too and I laid out a year ago. When viewed agenda is it all of course Ceos.
As we think that we Blanco would even be great. The generics business in the United States.
Build out there, especially franchise.
So it operational execution, and diversify where distribution channels.
We had a strong base for grows three core businesses, but are you done generics.
The hospital market put injectable drugs and the specialty pharmaceuticals, where we already had a growing presence in neurology and endocrinology.
In the past 12 months, we along with the 500 employees have been executing on three strategic priorities.
Yeah, we like the Companys generics R&D engine that combines the grandchildren specialty gotta, yet that's like I'd be extraordinary NK, one to seven successfully launched numerous new products when they grow nobody accretions he had cost structure.
In addition, we expanded our distribution with the acquisition of Africa, which gave us a new I would go up growth led the U.S. Federal agency sector.
Consequently, I mean now has a well diversified portfolio more than 250 approved products a best in class manufacturing organization in the United States, India and I line.
I'd like up new complex generics.
You know where new brands, we are moving forward, we though a strategy to double up more high revenue generics portfolio and a larger specialty business, let me quite an update on our progress risks and then you go Ajay portfolio with new products. So far we have launched stay wellbore target a theme new complex generic.
Products by 2021, Oh generic versions of new wedding and kind of it continued to perform strongly and we recently launched genetic look when is it which we also expect a portable well within the especially like myself the board golf products remain robust.
For the quarter right did you have any toward total prescriptions grew 8% go into Q2 thousand 19 successful execution of marketing strategies, that's due when top line growth as well as improved gross to net leading to a strong quarter for this segment.
Over time, we expect to the board a larger share what R&D spending to the specialty segment.
We seek Jack do business development of Portuguese that library, Jody existing glycol in CNS when endocrinology.
Moving onto our distribution strategy, we're very pleased with our <unk> acquisition riches, providing us with an attractive undepreciated assets.
We are expanding the optimizing unit goes business that have good see potential for additional up what's your use as well.
They dig nation has gone very well and over time, we would expect quote that extra they have parents growth. Let me go away. Some highlights on the second quarter results, starting with our generics business as we expect to call. We 19, how to put any negative impact demand of course, some products that aspiration.
Delayed.
Prestigious positions office visits.
We also temporary experienced larger than usual back orders due to supply chain disruptions. What example, we experienced manufacturing and packaging delayed I know in New York in New Jersey facility as those states where hit hard by the initial but are you up Cohen our wives.
However, I'm pleased to report that the situation a group as the quadrant progress Hey, we are now in a better position on Backorders and read but it didn't go up pretty good loads of finished goods that likely.
In the specialty business, we were pleased by the strong performance of right to the anybody growing which all state weakness of some other brands here to go ignite you.
This is the result of successful transition of marketing programs crop inputs into where she will position come quite a bit prescribing right to the on your it's hard to telemedicine ended a zillion CEO of recruits core those brands that money from light duty annuity toward increased 25, plus nine compared to Q2 2009.
Gee, highlighting our success, one commercial strategy and execution.
Turning to Emcare. This business continued to perform well, though what would cause some temporary delays and the launch of new products biological widens insight.
Moving forward strongly and continue to focus on operational excellence in this I put it shouldn't do and I laser welcome experience, having grown amnio chroma Barton startup grew more than they did I read your by 2017.
Coleman's through the cost started the year.
Despite the impact from Cowen <unk> gives us confidence as we continue to position and Neil.
Or long term success.
With that let me turn it over to Jim.
Thank you and your Doug Good morning, everyone.
It has been an eventful year since we've done it goes to you and react and to the I'd think about the progress we made thus far and significant opportunity.
Operational excellence over the course of fast here, we have significantly strengthened our supply chain and improved our operations our progress in reducing our backorder.
Was temporarily interrupted by the code pandemic, but the situation improved in June we are well positioned to meet volume demand a crossover manufacturing sites and see the potential for further improvement in these measures in the second half of the year.
We have been extremely impressed and proud off of it organizations ability to add up to the difficult circumstances caused by Kuwait 19.
After some initial disruption or operations recovered swiftly by the end of June more than 90% of employees were back to work at our U.S. manufacturing facilities.
Although the pandemic spread later in India. We're also seeing attendance back about 80% our facilities in India and Ireland, we have initiated multiple protocols at our facilities for the safety of our employees, including social distancing entering more screening we.
Oh also launched innovative information technology tools to enable our team to maintain productivity and to allow us to support and remain engaged with our employees. We appreciate that.
Hi, good work and commitment toward vision and expect to achieve over full year plant utilization targets. As originally said I would also like to highlight that while we continue to make operational improvements and get our operations back to full staffing we have maintained they were record for high quality with.
No actually issues.
We believe that our organizational structure also helped our ability to weather. The Colby disruption first we have a diversified supply chain with fixed manufacturing plant in India for across the USA and one in Ireland very substantial amount of redundancy between those.
<unk> plants as well as substantial amount of incremental capacity.
In addition, our EPA supply chain is fairly diversified without being overly reliant in any one supplier.
I would also like to spend I would like to spend the rest of my time talking about our R&D engine because it is truly the force that drives our company forward. As you know we are a mission oriented company and that mission has always been simple providing access to afford.
It was safe and effective medicines to as many patients as possible. The way, we built our company and our part to growth has and will always centered around value added signs even innovation I will start with generics, where we have a robust R&D deposit.
Men with over 750 scientists globally.
Our goal of transitioning over product portfolio to complex generics is progressing nicely. We expect to file 20 to 25 generic products in Twentytwenty, which consists talk mainly first to market and high value genetics, and we have 91 product in the pipeline awaiting equity.
The approval, we continue to focus on more complex products, including sterile injectable ophthalmic transdermal topical and installation formulation, which offers less intense competition higher margin and higher return on investment.
In addition, we have hundred 32 products.
Actively in development, mainly in non oral solid dosage forms.
I mean has a solid track record of filing getting approval and launching high value genetics quite instance, we recently announced approvals for neutron stars transdermal system and clue financing Hydrocolloid tablets, both launches speak to our team's ability to formulate.
Complex molecules navigate the regulatory landscape and ultimately launch ready valuable products.
Furthermore, we continue to improve the efficiency of our development process.
These gains not only improve our cost on a call product basis, but also allows us to file products at a faster pace than we've ever before as a result, we are seeing more launches each year, but to be more modest spending.
I will now turn to our specialty segment as you know we have a growing commercial presence in neurology and endocrinology led by unique right and rightfully. In addition, we are all seen were investing significant time and resources in specialty product development, which will become a bigger.
Driver of future growth.
For instance, our phase three clinical trial Court IP X two or three reaches over next generation carried over live video product for the treatment of Parkinson's.
Has resumed enrollment following a brief kiwi related interruption.
At this time, 70% to 75% of sites are open and screening patients.
We expect to have topline data in the second half or 2021 filed for approval in 22 and begin commercialization in late Twentytwenty Creed.
We're also continuing development work on K 127, and extended release tablets or by those take me for the treatment of my tenure gravis, which may be eligible for orphan disease designation. This program is very exciting and maybe ready for filing with the FDA as early as quarter.
One twentytwenty too.
We are enthusiastic about the prospect for specialty business and plan to direct Moraco, an R&D spending to this segment overtime, we expect to grow the specialty business, both organically and inorganically through selective in licensing got products and acquisitions.
Our focus as always is on therapeutic area that will leverage our strong infrastructure and capabilities.
Next I will provide a brief update on bio similars, where we have in licensed three oncologic products from external partners, our Neupogen Biosimilar program.
Currently filed and we await for the comments from equity.
We are very excited to announce our recent filing of our neulasta biosimilar and or whatever asking program is making good progress towards BLS submission.
Lastly, I would like to acknowledge our suppliers customers and employees for their efforts during the koby pandemic and thank them for their hard work and dedication during these challenging times.
I will turn the call over now to Tassos.
Thank you sent him net revenue during the quarter was 465 million up 60 million of 15% early Q2 2019.
Our current specialty were up 64 million and 24 million, respectively, while generics was down 20 million.
These results reflect the resiliency of our portfolio, which options temporary softness in demand you just call. It 90.
Approximately 20 million hold unfulfilled customer orders as our supply chain was stress.
And a negative 6 million adjustment for them its form and Rick.
Adjusted gross profit of 191 million.
As a 19 million or 9% compared to Q2 2090, reflecting solid performance. Despite the high level back orders in the form of course.
Adjusted gross margin of 41%.
It was 150, it's lower than Q2, 2019 and inline with our expectations.
Our care diluted our margins by 320 basis points, while the rest of the business margins grew by about 870 basis points.
On a sequential basis adjusted gross margin was also down due to an expected level price erosion.
Our manufacturing absorption and limits form in real.
Adjusted EBITDA 181 million was up 9 million or 9% come persecution 2019.
Care and the rest of the business contributed to growth.
Adjusted diluted EPS of 30 cents was favorable to the nine essentially reported in Q2 2019.
As higher adjusted EBITDA, and lower interest expense offset higher minority interest into outcome.
From an operating cash flow perspective, we're pleased to report a significant increase generating 179 million force the second quarter Twentytwenty.
Compared to the 21 million in Q2 2019.
This performance reflects our topline growth and favorable timing of collections in working capital.
Finally, our performance has improved financial flexibility.
Consequently at the end of the second quarter, we had 268 million in cash cash equivalents.
An additional 440 million available through our ABL facility.
And we also reduced our net debt to EBITDA ratio to six times versus seven times since the end of 2019.
In summary, we continue to deliver solid financial results and reducing our leverage ratio despite the challenging pandemic environment.
Let me now Moakler segment results, starting with generics well net revenue of 307 million was down 28 million from Q2, 2019 and down 46 million sequentially.
This performance reflects the following form factors first.
Compared to prior year 20 million of the 28 million reduction reflects the shift oxymorphone to the specialty segment.
The metformin recall and the divestment of our international operations.
Second as I mentioned earlier about 20 million of customer orders were from gone a scoping 19 adversely impacted our manufacturing operations.
We believe this is mostly behind us as back orders declined substantially.
Terror. It is well known to cover 90 has led to generally softer prescription trends and elective surgeries.
Some of the demand softness may also relate to early Filosa prescriptions in Q1 due to customer supply concerns, which we discussed in our prior may original.
Finally, our newer products such as El Arrayan should probably continue to perform well and our ability to resolve a number of within efforts supply issues were positive contributors in the quarter.
Adjusted gross margin for the generic said meant was largely in line with our expectations, a 35% compared to 34% in Q2, 2019 and 42% the prior quarter.
The sequential decline reflects price erosion slightly better than our expectations lower manufacturing absorption due to cope with 19, and then inform Enrico.
We expect that over the course of the year generics adjusted gross margins will improve as our supply chain recovers and it would further benefit from new product introductions.
Let me now turn to our specialty segment, which performed ahead of our expectations.
Net revenues of 94 million up 24 million from Q2 2019.
Adjusting for the reclassification more phone net revenues were up 40% versus prior year, driven by writer regulatory as expected covenant. It was a headwind, but solid commercial execution mitigated some of the negative impact.
On a sequential basis specialty net revenues were up 6 million or 7% demonstrating broke growth.
Adjusted gross margin for specialty segment was inline with expectations at 74% compared to 82% in Q2, 2019, and 75% prior quarter due to product mix and the reclassification more phone, which carries a lower margins than our other specialty products.
Let me now turn to occur, which supported net revenues of 64 million and adjusted gross margin of 21%.
This performance was in line with our expectations and reflects the durability in strong customer relations. So this business.
From a balance sheet perspective, as I mentioned earlier, we ended the quarter with 268 million in constant cash equivalent and no near term debt materials.
In addition, we fully repaid the 300 million.
Drawn from our ABL facility last quarter as markets to stabilize due to cover 90.
Looking to the second half of 2020, we feel confident on our ability to meet their financial commitments an annual guidance, we issued earlier this year.
As I did last quarter, let me provide some context.
First we have a growth portfolio and expect normalization of our manufacturing operations and overtime normalization of patient demand as well.
Second.
We expect improvements in our generics adjusted gross margin as we improve our ability to fulfill all customer orders and launch new products.
Third we expect an increase in operating expenses clinical sites speaking to open up and economic activity rebounds.
Finally from a cash flow perspective, we expect some reversal working capital and that being offset by the 110 million cash tax refund, we discussed last quarter.
With that I will turn it back to shore up. Thank you losses were proud of how well the company responded during the call retrain them. We continue to work on building the pipeline and operational excellence to execute the loan provision we have for the business I would like to now turn the call over to the operator could take your questions.
Thank you.
Well now begin the question answer session task. The question you May Press Star then one on your Touchtone phone.
For use in a speakerphone, please pick up your handset before pressing the keys.
We'll draw your question. Please press Star then too.
At this time, we'll pause momentarily to assemble a roster.
First question comes from Gregg Gilbert of Suntrust. Please go ahead.
Thanks, Gregg Gilbert with Trust Securities I have a brand one of those in a generic one first on the generic side I was curious on Nuvaring. It's.
Clear that some of your competitors or not so close but I had assumed it would be able to ramp more on the supply side.
Can you tell us what's going on there in terms of the ability to gain more share and whether there any issues preventing you from doing so.
And how long lasting you think that opportunity could be in light of kind of the competitive environment and perhaps Joe could comment on the brand side on the growth of writer in units right revenue versus prescriptions on what that disconnect is being driven by is that a quarterly.
Just quarterly variability or is there something else to understand about that dynamic. Thanks, a lot cash.
Good morning, Greg.
Sure I'll I'll take the first one and I'll pass it to Joe for the second question.
Oh, absolutely production has been ramped up we have doubled over capacity and we will be seeking additional market share starting this month.
Competitions, you know as much as we know.
Whenever that comes that comes by never market share would be.
In line to where 20, 25% to you when competition comps, we do not see our volume dropping because it's a two players today operation generics and us so its hard player coming in we shouldn't be able to maintain our what capacity.
Oh.
So we will take the sure. Thanks.
Henri Tiger $3 or get out LP script us a little bit.
Which is attributable to two factors, both price and volume price standpoint, we implemented some strategies at the end of last year to target more profitable patient segments than we've seen over the last two quarters. That's had a positive impact on gross to net from a volume standpoint, we saw a bolus of scripts in March and the inventory that kind of.
Replenished the trade shipped out in April so we had a little bit higher April a then what would have been expected because of restocking in the trade we saw that troubles retiring entries industry.
Thanks for that and if I could sneak in one follow up for truck engine to on the Biosimilar side I can certainly I understand your desire to be in that market long term.
Im a little concerned and curious about your thoughts on sort of the return potential for products like a vast and in the last if you're if you're not first or second or third and are you confident you can still get a good financial return if you're not among the first thank you very much.
Great question, Greg and this is as we've said before Biosimilar is a long term play.
It is more of a replay of affordable medicine.
And providing value to the system.
Fortunately for Amnio, we haven't invested that much of money in most of this so we'll return expectations, even though means for the six would be lower.
Offsetting the lower investment.
So we are focusing on oncology biosimilars and you're right. It is still quite important now if you were.
Courseware could slip as explained in the market. We are setting the stage as this becomes more of a crowded place, which we fully expect biosimilars to be and that was intended to be right. It is.
Yes.
And you can comment more on that.
Hi, there are being more open for new ideas and new science to not to highway expensive Biosimilar development and once that happens more biosimilars players will come it almost becomes like the generics business, yes. It has unfortunately today.
Specialty pharma kind of sales and marketing infrastructure. So you have genetics margin.
Branded sales and marketing they don't know together so we knew how to solve for this as I said, it's a long term play.
More and more competition will be expected in Los Angeles, you had to start.
Combining biosimilars to genetics.
Lisa Mohor competitors, all you're doing that.
And that's how it will play out and this is why we are just setting it up with low investment.
Being smart about it and opportunistic about how are we able to pipeline as we go forth.
So you want to comment on our FDA thinking more of a on there.
Development cycle.
Sure Hi, Greg Good morning, Biosimilar is evolving space and are.
There is lot more understanding from regulatory perspective are there any guidance before and after a year is willing to sit down with companies and explore new ideas that can be the approval and reducing the cost and you're absolutely right or but it's no wonder before sweepstakes. So we're looking at the portfolio, where we could be port.
I actually want to pretty but there are.
A lot more or other tools than just a full blown clinical studies that can be utilized to speed up.
That will look like a biosimilar in a very cost effective rate and that's what I'm big would be focusing on.
Thank you gentlemen.
Our next question comes from Randall Stanicky RBC capital. Please go ahead.
Hi, good morning misses the embassy on Forendo couple of questions first with respect to high value generic launches it sounds like you've got at least eight left over the next 12 months or so from your your targeted 15, how should we think about the cadence of those launches and specifically how many of those could we see over the remainder of 2020.
And second the midpoint of EBITDA guidance implies a sequential decline from the two Q level. During the second half is the right way to think about it and can you talk a little bit more about the puts and takes that go into that.
Is that driven largely by the step up in spend or are there other factors at play. Thank you.
I'll take the first one I'm sorry, I didn't catch your name off trend of sense no. It's not I know symbol, yeah, Dan Dan Busby, Okay. Thanks, sorry, sorry.
It was any clear.
Good morning. Thanks.
So yes, we are completely confident launching the remaining eight or 10 high value products, but the key is you should think about as we have really nicely.
R&D engine generics engine, we added 60, new projects, including Injectables, Ivy bags, and we ought to smaller blending injectables when we aim to become a meaningful Claire in coming years.
So now the pipeline is 132 products, so definitely will meet or what we say last year that will launch 15 to 20 high value products. We will I do not have inflammation or may not want to shed information that how many sales is coming up this year, but this is still looks good on.
New launches coming up on your guidance question, then I'm going to pass it to Tassos tests as you would you say architecture and good morning. So.
Yes, you're right with a month right. So it's a year to date we've had.
EBITDA of about 235 million.
We are projecting full year, who maintain our guidance between 400 $450 million. So appeal, we are expecting when you do the math is approximately the same level falls.
Performance in the second half as well as it for Scott, maybe a little maybe a little lower.
So here's the way we think about right. So we expect in the second half of the year.
Our business to continue to grow and that is.
Generics.
Continued to resolve our manufacturing backorder situation for launching new products of care will continue to do well.
And then the specialty specialty Q3, Q4, Q may come down slightly versus Q2 as some of the inventory.
Build up in Q2 that Joe mentioned normalizes.
But also we talked about we're expecting higher level of operating expenses.
Right. So number one is we're expecting a higher level of R&D expense.
We continue to invest.
In R&D and over time, a higher percentage of that specialty side, and then certainly we're expecting higher level Opex DNA expenses as the economy opens up and and we just can open up some of our sales and marketing.
Operating expenses plus so that's how we think about it this acceleration of revenue acceleration in operating expenses and at the end of the day right. We're still in the middle of the condemning so so that so that's what kind of year to date performance expectations about the future you still have any send known about the condemning.
Well that's worked out led us in our floor to maintain guidance, but the same time feel very confident or our ability to achieve.
Hopefully that gives you a little bit more color then.
Yeah, that's very helpful. Thank you.
So.
Thank you next question comes from Amy if audio.
Please go ahead.
Hi, Good morning, Thanks for taking my question I've got a helpful.
Let's have gone to Nivo pyroxene can you talk about saving but to get this product.
Competitive landscape.
Oh and can you give us an update on some of the pipeline products that you mentioned in the past.
Approval timelines oclock, so on and I believe you mentioned something about them in a product that could potentially get approved next yeah.
And then just knocked me.
So Kodak, let's see.
Uh huh known from the government can you talk about.
Neil as a company that may be positions to leverage some of its manufacturing footprint.
In that's domestication efforts and then can you talk to.
Solve the opportunity that thank you.
Thank you Amy good morning to you as well.
So the three questions you ask I'm really break it down I'm going to pause to address the genetic loads that oxen as you already know the competitions been doses last year.
But the product is also hard to switch so were large customer referred to stay with.
With the same product and we're able to manage or maintaining the volume. Obviously, we already had the price decline as you would expect lender who has came in.
Late last year and beginning of this year.
We should be should be okay, with the where we are today.
Your second question on how your third question on many taken plus and given the pipeline question to my brokerage and do so codag, yes. The Goldman afterwards, we are fully aware of.
Ward, they're trying to do have we been.
And then talks with us Goldman and legislators, we do believe in making essential products in the United States, because even the friendly countries, sometimes could have a situation where they are unable to shifted products. So we must produce certain of our.
Or certain percentages of our essentially drugs in the United States from the key starting material.
And finished products and name is well positioned and new is US domiciled company only market reserve is United States and we live in the United States. So we are completely vested on doing that I think obviously, we do want to be mindful of the cost that when you make products in the United.
States, which remain making lot of generic product in the United States still maybe one of the largest portfolio.
Than any other manufacturers, which are made in United States.
While bringing abiotic brings its own set of challenges with EPA and when the using the Green technologies may take some time up what enjoyable.
Finished products is much easier and we do believe that certain critical antibiotics and other emergency drug should be made here. So we'll see how are you progresses with the exactly do orders could do not much to sustain that the.
Industry in the United States for long term it will require legislative action and we hope as we hear from both sides.
Congrats and Republicans keen to to do something about this to do not have.
Our.
Secure supply chain for certain drugs in the United States.
Thats uptake from the from the government side and also the so two to four pipeline update.
Yes, Hi, Jamie good morning, So we're very excited about our pipeline and the.
The diversification ward to be ever done.
It's already strong pipeline and every dosage form of either capabilities from better looking into commercialization I mean, how was your question on come back. So for Copaxone is moving forward, we expect to launch starting second half broke brltwenty. One any later in the inhalation product is also moving rather be that you don't.
Have a form big yet, but most likely would be a 221 launch also and we already are excited on many are there are no cluster market in high value launches coming up over next 12 to 18 months.
HM Ginger if I could just have a quick follow up.
Obviously, there was a notable increasing the number or a pipeline assets. So that you haven't development can you give us some color on.
When we should expect.
These products.
Start hitting the market.
Maybe give a sense of venue.
The next two three years.
When do we start to see.
Those products get approved thanks.
Good so we have added more products, especially in the right injectable space or we have what do you can I do they were RMB Civeo baby ready accretion I'm personally very passionate about India and Oh, we are ready card pulling product selection.
Nor are we getting into commodity or projects. So our portfolio as you know you're including the theater. We are filing 22 Grand before most of them are close to bifurcate high value products.
So we really excited depending on the complexity of the broader it could be 12 to 18 months whatever two years, we'll be filing new new product. So these portfolio a would really be able to commercializing dread somewhere between 21 22 Grand degree, but we have no or you know what pipeline that.
Got excited about the growth potential from big Spike like.
Yes.
Hi, just just to add on the FDA Israeli appreciated as well as you know on improving lives, especially the first to market products and.
Different dosage form products over new development pipeline on slide nine onto a presentation you can see fundamentally do projects again, we added 60 projects, we are well known for years since 2007 of our pipeline and execution, we have been number one.
On bringing new products to the market that impression going pipeline. It's a generic business is running on a treadmill and we.
We've been running on effect will really well garden use doing so we feel very concrete and where do we saying in terms of generics business because over the size is such that we can still grow yes, we do expect every year competition.
But we have enough to offset that and grow and also look at the injectables that I mean bags, we added now.
We are good and execution and manufacturing quality, we have not equity years. We continue to will continue to do so so we expect good launches every year, it's not just the 18 to 24 months nominal.
Thank you.
Thank you next question comes from day, one that MISO Piper Jaffray. Please go ahead.
Yeah. Thanks.
So on Nuvaring I.
I guess this is one of those markets that even if sever where to get get an entry.
I would not be all that crowded overtime, so with that in line what.
Can you do the increase your capacity here and and by doing so grow your share maybe talk to that and then secondly, a question on right car and just the brand business in general I mean, if it.
You don't add additional assets focused on neurology. He looked at other therapeutic areas would write Terry and the next Gen product is something you would look at divesting and just I guess philosophically how do you how do you think about that in terms of either.
You know building the brand business or jettisoning.
Asset like right carried that yeah, and that may not be a an overall said thanks.
Well. Thank you David and then only good morning to you.
So new willingly as I mentioned before we doubled the capacity. So we are producing a weather on our automated lines plus automated parching.
And.
We will still keep working on growing the manufacturing capabilities and we have already modest share with the to the market. So I am sure anymore.
We'll see we'll get a more market share as we keep going and yes. It is a difficult products, it's a long term quarters.
So we would then and we have gotten good at manufacturing really good now so.
It's a good asset and durable asset for us and we will keep growing over manufacturing.
A way interesting question on the honest specialty so.
Think about this rate we have the foundation on Enginetics, which includes Injectables and now the bags.
Inhalation product they have calling products. All these are grow the airport US 19 per se is only on auto solid 81% of pipeline is on all the crude dosage forms. So we owe a base of 1.3 to 1.4 billion of genetics.
We still have room to grow in the United States.
So.
With having that foundation.
Especially engine, where we have right Terry or Joe Joe is doing a great job in it is the products.
We are great feedback from care wells accretion is much needed great stories, we're going to keep expanding dietary hey, we're going to where we have the.
The next two or three which almost doubles the time.
Good on time, so that is and we have learned a lot on the marketing and market. We are preparing already launched planning in 2023.
Whatever we do in light redo it would really well. So we are committed to specialty we'll be adding more assets. We also can you want to selling.
We know where it could get the platforms and technologies, we will we will buy companies.
And I'm very mindful of leveraged so we will not will be right because our goal is to get to five five below and then get to fourx, sometimes in near future so with increases in being die and.
Managing expenses in growing the business. So we are committed and we will be building, especially the movement disorder franchise and endocrinology other areas I'm not sure yet we are look we're always looking so.
We will load to know more about it as we keep going thank you Dave.
Okay. Thanks, that's helpful.
I guess, you're able to question.
Please press Star then one.
Your next question comes from different not from BMO capital. Please go ahead.
Hi, Good morning, I said Eli on for Gary. Thanks for taking my question I was wondering if you could provide an update on your partnership thoughts and to expand your international presence.
No the value first product and if you did if you can come close disclose what it is and if there any more products expected to be piled up for the remainder of the year. Thank you.
Hey, good morning, Gary.
Yes of course in partnership is progressing well.
Identified several ideal products, which which means that you wouldn't be filing we have been filing and we'll file mode. We're not at liberty to disclose those products as of now.
These products our daughter.
Have you approved products, which are really will be.
Be shipping from the United States lines, as well as Indian plans and potentially the island land as well and we're expanding the partnership as well looking at the other products we knew like.
China is a market is evolving so we'll see how how it goes everybody's learning the new ways of doing business they'll put together as chains have tha stolen.
But where do you exciting big market. So we have a good partner for soon and we.
We'll keep.
Sending over March.
Great. Thanks, and just as a follow up on that.
Yes, I talked about shipped to focus on your specialty franchise. So long term is there a directional target for mix, there for especially versus generics.
Are you, referring I'd say around the R&D spend.
So somebody like I can take it I think when when we look at the R&D spend right now each of these two thirds generics ones that are.
Specialty.
Maybe even more so skew towards generics overtime wed love to being that 50 50 split between between the two and we feel we can do these.
And without any impact to the strength of the pipeline on the generics.
So does that does address your question.
Yeah. That's helpful. Thank you.
Sure.
Weve reached the end the Mark when a session. Thank you for joining you may now disconnect.
No. Thank you everyone.
[noise].